Cardiff Oncology(CRDF)

搜索文档
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC
Globenewswire· 2025-06-18 04:05
– Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development – – Company will hold a conference call on July 29 at 4:30 p.m. ET/1:30 p.m. PT to share additional clinical data from its randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) – SAN DIEGO, June 17, 2025 (GLOBE ...
Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025
Globenewswire· 2025-06-03 04:05
文章核心观点 公司宣布评估onvansertib联合紫杉醇治疗转移性三阴性乳腺癌的1b期临床试验取得积极数据,该组合耐受性良好且毒性可控,最高剂量的onvansertib客观缓解率达40%,为开发onvansertib治疗多种癌症提供支持 [1][2][5] 公司概况 - 公司是临床阶段生物技术公司,利用PLK1抑制开发多种癌症新疗法,主要资产是onvansertib [4] - onvansertib正与标准疗法联用,针对RAS突变转移性结直肠癌等多种癌症开展临床试验 [4] 试验情况 - 试验由达纳 - 法伯癌症研究所的Antonio Giordano博士牵头,目的是评估onvansertib和紫杉醇组合的安全性、药代动力学和药效学 [5] - 研究主要终点是onvansertib加紫杉醇的安全性和剂量限制性毒性特征,确定推荐的2期剂量;次要终点包括药代动力学和药效学 [5] - 入组患者接受过中位数为3线的化疗 [5] 试验结果 - onvansertib联合紫杉醇在推荐2期剂量18mg/m(n = 10)时,根据RECIST 1.1标准客观缓解率达40%,有2例确认部分缓解和2例未确认部分缓解 [5] - 组合耐受性良好,毒性特征安全可控,最常见不良事件是骨髓抑制 [5] 公司观点 - 三阴性乳腺癌是最具侵袭性的乳腺癌亚型之一,开发新疗法满足患者需求十分紧迫 [2] - onvansertib加紫杉醇在患者中显示出强大疗效信号和可耐受的安全性,多数患者曾接受大量治疗,4例客观缓解中有3例患者曾使用过紫杉醇 [2] - 观察到剂量反应关系,最高剂量onvansertib客观缓解率达40%,研究结果验证了此前临床前数据中onvansertib和紫杉醇的协同作用 [2]
Cardiff Oncology (CRDF) Upgraded to Buy: Here's What You Should Know
ZACKS· 2025-05-15 01:05
评级升级与投资机会 - Cardiff Oncology(CRDF)近期被上调至Zacks Rank 2(买入评级) 主要反映盈利预期的上升趋势 这是影响股价的最强动力之一 [1] - Zacks评级体系的核心是追踪卖方分析师对当前及未来年度每股收益(EPS)的共识预期(Zacks Consensus Estimate) [1] - 该评级升级本质上是对公司盈利前景的积极评价 可能对其股价产生有利影响 [3] 盈利预期修正与股价关系 - 公司未来盈利潜力的变化(通过盈利预期修正体现)与短期股价走势存在强相关性 [4] - 机构投资者通过盈利预期计算公司公允价值 其大规模买卖行为会推动股价变动 [4] - 实证研究显示 跟踪盈利预期修正趋势对投资决策具有显著价值 [6] Zacks评级体系特征 - 该体系基于四项盈利相关因素将股票分为五类 从Zacks Rank 1(强力买入)到5(强力卖出) [7] - 自1988年以来 Zacks Rank 1股票年均回报率达+25% [7] - 体系覆盖4000多只股票 仅前5%获"强力买入"评级 接下来15%获"买入"评级 保持买卖评级均衡 [9] Cardiff Oncology具体数据 - 预计2025财年每股亏损0.82美元 较上年同期改善13.7% [8] - 过去三个月 Zacks共识预期已上调13.1% [8] - 当前2评级使其进入Zacks覆盖股票前20% 意味着近期可能上涨 [10] 行业研究方法论 - 盈利预期变化反映公司基本面改善 投资者应通过推高股价认可这种趋势 [5] - 位于Zacks覆盖股票前20%表明其具有优异的盈利预期修正特征 可能产生超额回报 [10]
Cardiff Oncology: Buying The First-Line Onvansertib Strategy
Seeking Alpha· 2025-05-14 21:05
投资组合筛选 - 在医疗保健领域筛选投资标的较为容易 因该领域存在大量潜在目标 [2] - 需将候选名单进一步缩小至10个高优先级生物制剂公司作为重点观察对象 [2] 投资策略 - 重点关注开发突破性疗法和/或具有被收购潜力的创新型制药公司 [2] - 当前持有IBRX和PFE的多头仓位 包括股票、期权或其他衍生品 [3] - 考虑在未来72小时内建立CRDF的多头仓位 [3] 研究服务 - 提供Compounding Healthcare订阅服务 可免费试用 以了解更多投资方法 [1]
Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates
ZACKS· 2025-05-09 06:25
财务表现 - 公司季度每股亏损0.20美元 低于Zacks共识预期的0.19美元亏损 但较去年同期0.22美元亏损有所收窄 [1] - 季度营收11万美元 大幅低于共识预期33.94% 同比下滑47.62% [2] - 过去四个季度中 公司两次超过每股亏损预期 三次超过营收预期 [2] 股价与市场表现 - 年初至今股价累计下跌42.6% 显著跑输同期标普500指数4.3%的跌幅 [3] - 当前Zacks评级为2(买入) 主要基于财报发布前盈利预期的上调趋势 [6] 未来展望 - 下季度共识预期为每股亏损0.19美元 营收17万美元 本财年预期亏损0.78美元 营收65万美元 [7] - 行业排名处于前33% 历史数据显示前50%行业表现优于后50%行业两倍以上 [8] 同业比较 - 同业公司Immatics预计季度每股亏损0.39美元 同比恶化875% 营收预期1490万美元 同比下滑54.7% [9]
Cardiff Oncology(CRDF) - 2025 Q1 - Quarterly Results
2025-05-09 04:10
Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update SAN DIEGO, May 8, 2025 -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. "Our lead program for onvansertib has remained on track in 2025 with the successful completion of enrollment in our trial in first-line ...
Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update
Globenewswire· 2025-05-09 04:05
- Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) - - Expanded intellectual property portfolio with second patent covering treatment of all bev-naïve patients, including RAS-mutated and RAS wild-type mCRC, across all lines of therapy - - Cash and investments of $79.9 million as of March 31, 2025, projected runway into Q1 2027 - SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Card ...
Cardiff Oncology(CRDF) - 2025 Q1 - Quarterly Report
2025-05-09 04:00
Table of Contents For the transition period from to COMMISSION FILE NUMBER 001-35558 CARDIFF ONCOLOGY, INC. (Exact Name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 27-2004382 (State or other juris ...
Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon
Seeking Alpha· 2025-05-02 15:35
文章核心观点 - 卡迪夫肿瘤公司是结直肠癌领域一个有趣的小型生物技术公司,其随机2期试验的主要数据显示出巨大潜力 [1] 公司情况 - 卡迪夫肿瘤公司在纳斯达克上市,专注结直肠癌领域,随机2期试验主要数据显示有较大潜力 [1]
Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Should You Buy?
ZACKS· 2025-04-24 23:09
Wall Street expects a year-over-year increase in earnings on lower revenues when Cardiff Oncology (CRDF) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock ma ...